 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an...

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral...

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mereo BioPharma assumed with a Buy at BTIG

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in...

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Mereo BioPharma expects cash to fund requirements into 2026

LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report) and Longeveron (NASDAQ:LGVN  Get Free Report) are both small-cap medical companies, but which is the superior business? We will...

Analyzing Mereo BioPharma Group (NASDAQ:MREO) & Longeveron (NASDAQ:LGVN)

Needham & Company LLC restated their buy rating on shares of Mereo BioPharma Group (NASDAQ:MREO Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Mereo BioPharma Group Price Performance MREO stock opened at $1.60 on ...

Mereo BioPharma Group (NASDAQ:MREO) Earns Buy Rating from Needham & Company LLC

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report)s stock had its buy rating restated by stock analysts at Needham  Company LLC in a research note issued on Wednesday, Benzinga reports. They presently have a $5.00 target price on the stock. Needham  Company ...

Mereo BioPharma Group (NASDAQ:MREO) Rating Reiterated by Needham & Company LLC

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Watchers	4,940
52-Wk Low	$0.4945
52-Wk High	$2.39

Market Cap	$243.95M
Volume (M)	1.73M
52-Wk High	$2.39
52-Wk Low	$0.4945

MREO Mereo Biopharma

About

Feed

News

Sentiment

Fundamentals